New drug cocktail targets myeloma tumors outside the bone marrow
NCT ID NCT06627751
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—in 28 patients with multiple myeloma that has returned or not responded to treatment and has spread to soft tissues or organs. The goal is to see if this combo can shrink tumors or keep the disease from getting worse. Participants will receive the drugs in cycles and be monitored for side effects and response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mezigdomide, carfilzomib, and dexamethasone
- What this could lead to
- If it works, this could offer a new treatment option for patients with multiple myeloma that has spread outside the bone marrow and is hard to treat.
- What could go wrong
- This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. The drug combination may cause side effects like infections or heart issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Double-barreled CAR t therapy takes aim at hard-to-treat myeloma
- Can a drug stop dangerous side effects of new myeloma therapies?